1. Denmark Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
H. Lundbeck A/S Class A

H. Lundbeck A/S Class A

6.46
EUR
+0.18
(+2.87%)
0.52EPS
9.35P/E
4.86BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
77.79
68.63
74.28
79.29
87.52
89.97
87.36
88.92
16.41
18.38
20.07
22.19
24.83
26.18
Basic EPS, GAAP
4.36
-0.78
-28.98
6.14
13.29
19.67
11.64
7.96
1.33
1.93
2.31
3.17
3.22
3.91
Free Cash Flow per Basic Share
11.45
0.31
-14.04
14.12
16.81
26.56
10.9
16.9
1.67
2.72
3.61
2.78
4.9
5.85
Dividend per Share
2
2.77
- -
- -
2.45
8
12
4.1
0.5
0.4
0.58
0.7
0.95
1.15
Book Value per Share
68.71
68.87
44.53
49.12
61.32
71.71
84.46
85.42
92.02
20.93
22.22
25.23
25.1
27.07
Tangible Book Value per Share
22.45
4.36
-5.11
4.33
23.24
31.34
-47.67
-29.01
-22.51
-1.73
1.36
-16.16
-10.96
-9.23
Basic Weighted Avg Shares
196
196
196
197
198
199
199
199
993
993
992
991
992
992
Sales/Revenue/Turnover
15,258
13,468
14,594
15,634
17,286
17,875
17,358
17,672
16,299
18,246
19,912
22,004
24,630
25,960
Operating Margin (%)
10.48
0.74
-46.7
14.66
25.8
28.3
20.02
11.26
12.33
15.63
16.05
14.86
21.42
21.8
Depreciation Expense
- -
1,453
7,026
1,554
- -
- -
1,670
2,793
1,710
1,811
2,012
1,876
1,865
- -
Net Income, GAAP
855
-153
-5,694
1,211
2,624
3,907
2,313
1,581
1,318
1,916
2,290
3,143
3,192
3,880
Effective Tax Rate (%)
41.92
- -
- -
43.86
38.65
26.13
23.56
17.05
16.64
22.55
23.49
15.49
28.86
27.73
Profit Margin (%)
5.6
-1.14
-39.02
7.75
15.18
21.86
13.33
8.95
8.09
10.5
11.5
14.28
12.96
14.95
Working Capital
4,845
2,184
-88
-252
2,365
4,073
-1,242
93
-206
3,213
5,299
4,430
3,930
3,435
LT Debt
2,141
3,259
3,687
1,708
57
- -
7,499
5,813
5,236
5,491
4,065
16,611
11,580
9,346
Total Equity
13,481
13,526
8,785
9,694
12,181
14,251
16,782
16,973
18,279
20,779
22,045
25,010
24,903
26,865
Return on Invested Capital (%)
6.04
- -
- -
10.6
22.55
29.49
11.71
6.3
6.76
8.67
9.12
8.04
9.48
10.91
Return on Capital (%)
6.62
- -
- -
11.46
23.64
29.5
11.63
6.76
5.97
7.99
8.87
9.54
9.09
10.47
Return on Common Equity (%)
6.41
-1.13
-51.04
13.11
23.99
29.56
14.91
9.37
7.48
9.81
10.69
13.36
12.79
15.2

Capital Structure

DKK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
74
74
71
LT Borrowings
11,185
10,446
8,955
LT Finance Leases
395
408
391
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
992
992
992
Market Capitalization
35,822
33,445
36,305

Working Capital

DKK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
12,783
12,647
12,807
Cash, Cash Equivalents & STI
3,433
1,956
2,196
Accounts Receivable, Net
3,605
6,092
6,227
Inventories
4,473
4,599
4,384
Total Current Liabilities
8,853
8,991
9,372
Payables & Accruals
- -
- -
- -
ST Debt
74
74
71
Deferred Revenue
- -
- -
- -

Growth Rates

DKK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.24%
8.1%
-0.43%
Free Cash Flow
-2.87%
19.58%
76.13%
Net Income, GAAP
5.89%
17.41%
1.56%
Sales/Revenue/Turnover
5.58%
7.15%
11.93%
Total Cash Common Dividend
- -
8.46%
35.88%

Quarterly Revenue

DKK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,288
5,453
5,722
5,541
22,004
2025
6,235
6,023
6,279
6,093
24,630
2026
7,125
6,463
- -
- -
- -

Quarterly Earnings Per Share

DKK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.01
0.78
0.78
0.6
3.17
2025
1.13
0.95
1.11
-0.03
3.22
2026
1.67
1.16
- -
- -
- -

Quarterly Dividends Per Share

DKK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.7
- -
- -
- -
0.7
2025
0.95
- -
- -
- -
0.95
2026
1.15
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Charl van Zyl
Full Time Employees
5,214
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Ottiliavej 9 Valby CR Denmark 2500
IPO Date
Jan 1, 1999
Website
lundbeck.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
H. Lundbeck A/S is a Danish international pharmaceutical company specializing exclusively in the research, development, manufacturing, and commercialization of pharmaceuticals for the treatment of psychiatric and neurological disorders. The company’s core products include proprietary pharmaceuticals addressing brain diseases such as depression, anxiety, schizophrenia, Alzheimer's disease, Parkinson's disease, epilepsy, and other central nervous system disorders. It offers a wide portfolio with key strategic brands including Vyepti for migraine, Trintellix for depression, and Rexulti for schizophrenia and bipolar disorder, alongside several investigational drugs for neuro-rare and neuro-specialty diseases. Lundbeck markets its products globally, with registration in over 100 countries and operations spanning Europe, North America, and international markets. The company is headquartered in Copenhagen, Denmark, was founded in 1915, and maintains manufacturing facilities in Denmark, France, and Italy as well as research centers in Denmark and the United States. In 2024 and 2025, Lundbeck has pursued significant strategic developments enhancing its market presence and pipeline strength. In October 2024, Lundbeck agreed to acquire Longboard Pharmaceuticals, a U.S.-based epilepsy drug manufacturer, in a $2.6 billion deal, representing its largest acquisition to date. This acquisition strengthens Lundbeck’s neurology portfolio, especially in developing treatments for epilepsy and related central nervous system conditions. Additionally, in September 2025, Lundbeck initiated a major commercial transformation, transitioning its operations in 27 European and international markets to a partnership model with entities such as Swixx Group, Zuellig Pharma, and NewBridge Pharmaceuticals. This strategic shift aims to sharpen commercial focus, reduce operational complexity, and reallocate capital to high-growth neuro-rare and neuro-specialty disease franchises. In 2025, Lundbeck also showcased progress with investigational molecules such as amlenetug for multiple system atrophy, emphasizing advanced clinical development programs leveraging innovative methodologies. Lundbeck operates primarily within the pharmaceuticals and biotech industry, targeting healthcare providers, hospitals, and specialty clinics treating brain disorders. The company has approximately 5,600 employees and is publicly listed on the Copenhagen Stock Exchange. Its strategic priorities revolve around expanding its leadership in brain diseases through a focused innovator strategy, driven by robust research and development capabilities and a growing late-stage pipeline of neuro-rare and neuro-specialty disease treatments. The recent changes reflect Lundbeck’s commitment to strengthening its global footprint, optimizing commercial execution, and advancing novel therapies for enduring neurological and psychiatric conditions.

Company News

Company News APIChatGPT

  • seekingalpha.com

    H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript

  • seekingalpha.com

    H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript

  • wsj.com

    H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal

  • seekingalpha.com

    H. Lundbeck A/S (HLBBF) Q3 2025 Earnings Call Transcript

  • prnewswire.com

    Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan